Next Article in Journal
Insights into the Two Most Common Cancers of Primitive Gut-Derived Structures and Their Microbial Connections
Previous Article in Journal
Diagnostic Challenges in Follicular Cholangitis Mimicking Hilar Cholangiocarcinoma: A Case Report and Review of the Literature
Previous Article in Special Issue
Transcranial Corticospinal Motor-Evoked Potentials in Cases of Ventral and Ventrolateral Intradural Extramedullary Cervical Spinal Cord Tumors
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Increased Dose in Spine Stereotactic Radiosurgery for Metastatic Disease: Are We Underestimating the Risks?

1
Department of Neurological Surgery, Sheba Medical Center, Ramat Gan 5262000, Israel
2
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv 6139001, Israel
3
Department of Orthopedics B and Spine Surgery, Galilee Medical Center, Nahariya 2210001, Israel
4
Radiation Oncology Unit, Oncology Institute, Sheba Medical Center, Ramat Gan 5262000, Israel
*
Author to whom correspondence should be addressed.
Medicina 2024, 60(9), 1514; https://doi.org/10.3390/medicina60091514
Submission received: 23 July 2024 / Revised: 14 September 2024 / Accepted: 16 September 2024 / Published: 17 September 2024
(This article belongs to the Special Issue Spinal Tumors)

Abstract

Background and Objectives: The recently published Spine Stereotactic Radiosurgery (SSRS) ESTRO guidelines advise against treating spinal metastatic disease with a single dose equal to or smaller than 18 Gy, prioritizing local control over the potential for complications. This study aims to assess the necessity and validity of these higher dose recommendations by evaluating the outcomes and experiences with lower radiation doses. Materials and Methods: A retrospective evaluation of SSRS patients treated at a single institute was conducted. The outcomes and complications of this cohort were compared to the current literature and the data supporting the new ESTRO guidelines. Results: A total of 149 treatment sessions involving 242 spinal levels were evaluated. The overall local control rate was 91.2%. The mean radiation dose for the local control group compared to the local failure group was similar (17.5 vs. 17.6 Gy, not significant). The overall complication rate was 6%. These results are consistent with previous publications evaluating SSRS for metastatic spinal disease. Conclusions: SSRS dose escalation may increase local control efficacy but comes with a higher risk of complications. The evidence supporting the strong recommendations in the recent ESTRO guidelines is not robust enough to justify a universal application. Given the palliative nature of treatment for metastatic patients, dose determination should be individualized based on patient conditions and preferences, with a detailed discussion about the risk–benefit ratio of increased doses and the level of evidence supporting these recommendations.
Keywords: spine tumors; spine radiosurgery; stereotactic body radiotherapy; guidelines; radiation dose spine tumors; spine radiosurgery; stereotactic body radiotherapy; guidelines; radiation dose

Share and Cite

MDPI and ACS Style

Kimchi, G.; Nulman, M.; Haj, S.; Bar-Orian, I.; Haisraely, O.; Harel, R. Increased Dose in Spine Stereotactic Radiosurgery for Metastatic Disease: Are We Underestimating the Risks? Medicina 2024, 60, 1514. https://doi.org/10.3390/medicina60091514

AMA Style

Kimchi G, Nulman M, Haj S, Bar-Orian I, Haisraely O, Harel R. Increased Dose in Spine Stereotactic Radiosurgery for Metastatic Disease: Are We Underestimating the Risks? Medicina. 2024; 60(9):1514. https://doi.org/10.3390/medicina60091514

Chicago/Turabian Style

Kimchi, Gil, Maya Nulman, Saeda Haj, Idan Bar-Orian, Ory Haisraely, and Ran Harel. 2024. "Increased Dose in Spine Stereotactic Radiosurgery for Metastatic Disease: Are We Underestimating the Risks?" Medicina 60, no. 9: 1514. https://doi.org/10.3390/medicina60091514

APA Style

Kimchi, G., Nulman, M., Haj, S., Bar-Orian, I., Haisraely, O., & Harel, R. (2024). Increased Dose in Spine Stereotactic Radiosurgery for Metastatic Disease: Are We Underestimating the Risks? Medicina, 60(9), 1514. https://doi.org/10.3390/medicina60091514

Article Metrics

Back to TopTop